Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM)

K-Number: K896582 · 1990-06-28

ApplicantPrimus, Inc.
Decision Date1990-06-28
Product CodeLCP
Advisory CommitteeHE
DecisionSubstantially Equivalent

Device Summary

DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM) is the device name listed in this FDA 510(k) record. The listed applicant is Primus, Inc.. It received FDA 510(k) clearance on 1990-06-28 under 510(k) number K896582. The device is classified under product code LCP. It was reviewed by the HE advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM)?

DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM) is a medical device that received FDA 510(k) clearance on 1990-06-28. The listed applicant is Primus, Inc.. The 510(k) number is K896582.

When did DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM) receive FDA 510(k) clearance?

DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM) received FDA 510(k) clearance on 1990-06-28, under 510(k) number K896582.

Who is the listed applicant for DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM)?

The FDA 510(k) record lists Primus, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM)?

The FDA product code for DIABETES CARE(TM) TEST PACKAGE FOR THE CLC 330(TM) is LCP.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Primus, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K993131NYCOCARD HBA1C GLYCOSYLATED HEMOGLOBIN ASSAYK891235PRIMUS MODEL CLC 330

Related Devices (Code: LCP)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K221326Nova Allegro HbA1c Assay, Nova Allegro AnalyzerNova Biomedical CorporationK231465Q-Pad Test SystemQurasenseK214117Afinion™ HbA1c, Afinion™ 2 and Alere Afinion™ AS100 AnalyzerAbbott Diagnostics Technologies ASK192987Aina HbA1c Monitoring System 2Jana Care, Inc.K192369PixoTest POCT System - PixoTest POCT Analyzer and PixoTest A1c Test KitIxensor Co, Ltd.K183230OneDraw A1C Test SystemDrawbridge Health, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑